Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $500.5M

Overview

Freenome is a pioneering diagnostics company developing a multiomics and AI-powered platform for early cancer detection via blood tests. Founded in 2014 and headquartered in South San Francisco, the company's lead program is a blood-based screening test for colorectal cancer (CRC), which is undergoing validation in the large-scale PREEMPT CRC study. Freenome is also expanding its pipeline into lung cancer detection and aims to create a broad, accessible screening platform to improve cancer outcomes through earlier intervention.

Oncology

Technology Platform

A multiomics platform combining computational biology, machine learning, and analysis of multiple data types from blood (e.g., cell-free DNA, methylation, fragmentomics, proteins) to detect early-stage cancer.

Funding History

4
Total raised:$500.5M
Series C$270M
Series B$160M
Series A$65M
Seed$5.5M

Opportunities

The massive, underserved market for convenient cancer screening, particularly for colorectal and lung cancers, presents a multi-billion dollar opportunity.
Success with initial tests could enable expansion into a multi-cancer early detection (MCED) platform, representing a paradigm shift in preventive healthcare.

Risk Factors

Key risks include the failure of pivotal clinical trials to demonstrate sufficient sensitivity/specificity, challenges in obtaining FDA approval and broad insurance reimbursement, and intense competition from well-funded rivals in the liquid biopsy space.

Competitive Landscape

Freenome competes in the crowded liquid biopsy for early detection market against companies like Exact Sciences (Cologuard, MCED), Guardant Health (Shield), and Grail (Galleri). Differentiation is based on its multiomics platform and the scale of its clinical validation studies.